

Company Overview

OncoSec Medical Incorporated is a biopharmaceutical company developing its investigational immunotherapy, TAVO, for the treatment of cancer. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of TAVO have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating TAVO for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate TAVO in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

OncoSec Enters Research Collaboration Agreement with UCLA and Roger S. Lo, M.D., Ph.D.

Aug 6 2018, 8:00 AM EDT

OncoSec Appoints Robert W. Ashworth, Ph.D. as Vice President, Regulatory

Jul 30 2018, 8:00 AM EDT

OncoSec Presents Update from Triple Negative Breast Cancer Program at 3rd Global Insight Conference on Breast Cancer

Jul 17 2018, 8:00 AM EDT

Stock Overview

Symbol	ONCS
Exchange	Nasdaq
Market Cap	74.33m
Last Price	\$1.42
52-Week	\$0.88 - \$2.95

08/20/2018 04:00 PM EDT

Investor Relations

T: 855-ONCOSEC (855-662-6732)
investors@oncosec.com

Management Team

Daniel J. O'Connor

Chief Executive Officer, President and Director

Sara M. Bonstein

Chief Financial Officer and Chief Operating Officer

Christopher G. Twitty, Ph.D.

Chief Scientific Officer

Sharron Gargosky, PhD

Chief Clinical Officer

OncoSec Medical Incorporated

3565 General Atomics Ct.
San Diego, CA 92121

24 Main St.
Pennington, NJ 08534

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.